AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00685776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
Study NCT00685776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Participants will receive one placebo tablet once daily for 76 weeks.
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Study NCT00596076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month.
Study NCT00323466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMRT versus conventional radiotherapy
Description: Comparing MRT versus conventional radiotherapy
Study NCT01906515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive hemoglobin monitoring
Description: Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
Study NCT03450044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells
Description: Adoptive transfer of autologous DCs
Study NCT04292288 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical observational
Description: no intervention - observational
Study NCT02985216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO
Study NCT02985216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Study NCT03483363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)
Description: Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
Study NCT03483363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical irrigation with sterile normal saline (NS)
Description: Fractures will be irrigated with sterile normal saline prior to closure.
Study NCT03483363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) prophylactic antibiotic
Description: All arms with receive standard parenteral (IV) prophylactic antibiotic.
Study NCT03483363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) prophylactic antibiotic
Description: All arms with receive standard parenteral (IV) prophylactic antibiotic.
Study NCT01797237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFNA
Study NCT01777256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Study NCT03922425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mental health team
Description: CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
Study NCT01797237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterTAN
Study NCT04185623 — intervention group
Intervention type: PROCEDURE
Intervention: denudation time lag
Description: The time between ovum pickup and denudation of oocyte
Study NCT03225625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal EX
Description: BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
Study NCT03225625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal VR
Description: BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
Study NCT01556594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 1 mg
Study NCT01556594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 2 mg
Study NCT00658515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Description: 600mg po daily
Study NCT00901446 — intervention group
Intervention type: DEVICE
Intervention: Intravascular ultrasound and spectroscopy
Description: Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
Study NCT01169142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 50,000 units of Vitamin D3 weekly
Study NCT01169142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 units weekly
Study NCT04049123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC
Study NCT04049123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT01355341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HERBMED PLUS
Description: 500 mg Twice day for 6 month with lunch and dinner.
Study NCT00296894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg sc every other week)
Description: Adalimumab (40 mg sc every other week)
Study NCT00296894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00658515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evidence-based medical care for Acute Coronary Syndrome
Description: As prescribed
Study NCT00658515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evidence-based medical care for Acute Coronary Syndrome
Description: As prescribed
Study NCT00658515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study NCT03408535 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eriksholm Guide to Better Hearing
Description: Online rehabilitation program.
Study NCT01713452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purse string closure
Description: 1. An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~2. Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~3. Diameter of the skin defect should then be measured.~4. A postoperative photo will then be taken.
Study NCT01713452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure
Description: 1. An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~2. Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (\<1.5cm). No subcutaneous drains will be placed.~3. Length of the incision should be measured in centimeters.~4. A postoperative photo will then be taken.
Study NCT00931814 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise training
Description: A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
Study NCT03338855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2.
Study NCT03338855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2.
Study NCT03404557 — intervention group
Intervention type: OTHER
Intervention: Proteomic analysis
Description: Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
Study NCT01114100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
Study NCT01114100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
Study NCT04139759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand massage
Description: In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
Study NCT04139759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
Study NCT04104412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell
Description: 2\*10\^7
Study NCT01352299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope blade
Description: Laryngoscopy performed with Macintosh Laryngoscope
Study NCT00946816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Nutritional Intervention
Study NCT01556594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC Glucagon
Study NCT01556594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 3 mg
Study NCT02576691 — intervention group
Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Study NCT03578978 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to study subjects. Only blood will be obtained from study subjects.
Study NCT02797665 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
Study NCT03833986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress management program
Description: Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
Study NCT04236180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialised Paediatric Palliative Care (SPPC)
Description: All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
Study NCT02519894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Scanning Calculator
Study NCT04821700 — intervention group
Intervention type: BIOLOGICAL
Intervention: Carotid Stenosis
Description: To investigate if the concurrent presence of carotid stenosis has any effect on future outcomes of patients with ischemic stroke and atrial fibrillation
Study NCT00245830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
Study NCT00754715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Solution administered once orally
Study NCT00754715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution administered only once
Study NCT01461928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Induction Period)
Description: Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
Study NCT01352299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MacCoy
Description: Laryngoscopy performed with MacCoy Laryngoscope
Study NCT01352299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller
Description: Laryngoscopy performed with Miller Laryngoscope
Study NCT04942743 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI OF TMJ
Study NCT02862561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02862561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02862561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cells
Description: DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT01352299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TrueView
Description: Laryngoscopy performed with TrueView laryngoscope
Study NCT01379547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Procalcitonin guided antibiotics treatment algorithm
Description: Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
Study NCT01379547 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
Study NCT01189812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: 300 mg one time per day for 4 weeks
Study NCT01189812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one time daily for 4 weeks
Study NCT01189812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
Study NCT01189812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Description: All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
Study NCT02744391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Study NCT01461928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Induction Period)
Description: Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
Study NCT01461928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab
Description: Participants will receive rituximab according to the regimen specified in individual arm.
Study NCT01461928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab according to the regimen specified in individual arm.
Study NCT03263858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Implantation of coronary stent in de novo coronary artery lesions
Study NCT03761888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: optic nerve sheath measurement and transcranial doppler
Description: evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% once daily
Description: Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% twice daily
Description: Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% once daily
Description: Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% once daily
Description: Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle once daily
Description: Vehicle topical spray administered to affected areas once daily for 28 days
Study NCT01018134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle twice daily
Description: Vehicle topical spray administered to affected areas twice daily for 28 days
Study NCT02242435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion
Study NCT02242435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Study NCT03366558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UPDRS questionnaires
Description: UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
Study NCT03366558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 20-step walking test
Description: 20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
Study NCT02557100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT02557100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Study NCT02557100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT02557100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02557100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT02710123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-Threshold exercise prescription
Description: Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
Study NCT02710123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Structured stretching prescription
Description: Participants will be given a prescription for daily stretching lasting approximately 20 minutes.